Morgan Stanley Analysts Handicap Potential Switches In Near Future

With the potential to cash in on up to $10 billion in branded sales in the next five years, a number of prescription drugs are positioned to break into the OTC market by 2012, Morgan Stanley analysts say

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet